Molecular Formula | C122H242O50 |
Molar Mass | 2509.2 |
Storage Condition | -20 ℃, dry, sealed |
In vitro study | NP-3 (0.05-1.6 mg/mL; 24 hours) does not decrease the cytotoxicity of cells in 293T, HepG2, A549, and HeLa cell lines, but the DPPC and DMG-PEG coated nanoparticles reduce cell cytotoxicity. In addition, the transfection efficiency of DPPC/DMG-PEG/(lPEI/DNA) nanoparticles (NP-3) in 293 cells is improved, and the maximum transfection efficiency (∼76% eGFP positive cells) is observed. |
In vivo study | NP-3 (oral administration; 150 μg DNA per mouse; single dose) at 12, 24, and 36 h postadministration, luciferin substrate is intraperitoneally injected to verify its permeability. NP-3 group maintains high luciferase expression in the liver, lung, and intestine areas 12-24 h post-treatment.Additionally, NP-3 exhibits 1.5 times higher signal intensity than that of NP-1 or NP-2 group from 12 to 24 h postoral administration. |
biological activity | DMG-PEG 2000 for the preparation of liposomes for siRNA delivery, the transfection efficiency can be improved. DMG-PEG 2000 can also be used for the preparation of lipid nanoparticles for oral delivery of plasmid DNA in vivo, DMG-PEG 2000 can improve the mucus permeability and delivery efficiency of nanoparticles. |